Drugs / GS3-007a
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07473570 | Jan → Jun 2026 overdue | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07264595 | Dec 2025 → Nov 2030 expected | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07259564 | Dec 2025 → Apr 2026 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS3-007a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07473570 ↗ |
| Route | Oral | “drinking solution” NCT07259564 ↗ |